Navigation Links
Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
Date:1/7/2009

UCB's Keppra XR Will Become the Gold Standard Adjunctive Treatment for Partial-Onset Epilepsy by 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists would welcome an adjunctive antiepileptic drug (AED) that is administered once-daily. According to U.S. neurologists, a drug of this type would earn a 25 percent patient share in epilepsy and according to European neurologists, such an agent would earn 35 percent patient share. According to the new report entitled Epilepsy: Opportunity Exists for Improved AEDs Despite Numerous Market Pressures, these robust patient shares highlight surveyed neurologists' keen interest in AEDs with less-frequent dosing. Nevertheless, these patient shares are considerably higher than those typically attained by adjunctive AEDs, given neurologists' generally conservative adoption of new epilepsy therapies as well as adjunctive AEDs' use primarily in refractory patients. Consequently, it is not expected that emerging adjunctive AEDs will capture such generous patient shares.

The report also finds that UCB's Keppra XR will earn Decision Resources' proprietary clinical gold standard status for the adjunctive treatment of partial-onset epilepsy by 2012 as interviewed specialists indicate that the drug has competitive advantages in safety and delivery attributes over GlaxoSmithKline's sales-leading Lamictal. According to surveyed neurologists, Keppra XR is perceived as having a lower risk of serious side effects and offers the advantage of once-daily dosing, which is considered to be the ideal AED dosing frequency for epilepsy patients.

"With its high cost and the high level of physician comfort in prescribing the drug as an add-on therapy, Lamictal became the epilepsy sales leader in 200
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
2. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
3. Morgan Fairchild Joins Neurologists, Emergency Physicians and the American Stroke Association to Educate the Public About Stroke Symptoms
4. Despite Availability of Generic Equivalents, Two-Thirds of Neurologists Will Continue to Prescribe Branded Anti-Epileptic Drugs to Epilepsy Patients
5. Eligard(R) six-month formulation successfully completes European approval procedure
6. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
7. Medical Services International Inc. Completes Testing for European Union (EU) Application
8. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
9. Europe-wide Researchers Night
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Launch of second European Cancer Research Funding survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 The Clinical Data Interchange ... the International Organization for Standardization (ISO) now recognizes ... Model version 3.2 as a published, Final International ... healthcare. This standard, which had previously passed through ... unanimously approved on 24 April for publication by ...
(Date:5/28/2015)... The Boys & Girls Club of Atlantic ... Cross Blue Shield of New Jersey (Horizon BCBSNJ) and through ... can receive much more support as play begins for the ... Boys & Girls Club member and volunteer with the organization ... has accepted the Horizon Blue Cross Blue Shield of New ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Are policies ... after a hospital stay triggering financial pain for seniors? ... American Journal of Managed Care set to figure out, ... recent federal rule change. , The study, “Observation Encounters ... A. Vashi, MD, MPH, examined how Medicare policies that ...
(Date:5/28/2015)... ISMETT , a leading transplant hospital ... Sicilian economy by €132.5 million in expenditure in 2013, generated ... than €73 million by retaining patients who otherwise would have ... study by the Battelle Memorial Institute. At the same time, ... advanced health care management that is transforming Sicily into a ...
(Date:5/28/2015)... 2015 Workers’ compensation costs per claim in ... recent study by the Workers Compensation Research Institute ... period. , The WCRI study, CompScope™ Benchmarks for Michigan, ... seven days or more of work with those of 16 ... Michigan claim was 4 percent lower than similar claims from ...
Breaking Medicine News(10 mins):Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 2Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 3Health News:Golf Pro Natalie Gulbis to Chip in with Horizon Blue Cross Blue Shield of New Jersey to Support Boys & Girls Club of Atlantic City 2Health News:Golf Pro Natalie Gulbis to Chip in with Horizon Blue Cross Blue Shield of New Jersey to Support Boys & Girls Club of Atlantic City 3Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 2Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 3Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 3Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2
... , , HARRISBURG, Pa., July ... received free dental care, valued at nearly $160,000, in the ... United Concordia Dental. , , ... provide free preventive services to those who cannot afford dental ...
... , INDIANAPOLIS, July 23 Today, ... that the U.S. Food and Drug Administration (FDA) has approved ... origin) injection] to treat osteoporosis associated with sustained, systemic glucocorticoid ... Glucocorticoid therapy is the most common cause of secondary osteoporosis, ...
... Cancer stem-like cells have been implicated in the ... at Cedars-Sinai Medical Center,s Maxine Dunitz Neurosurgical Institute have ... these "mother" cells to generate new tumors in laboratory ... a possible strategy in the fight against malignant and ...
... , , , , ... Program (NCDP), a program of Novo Nordisk, and several member associations today ... and treatment of diabetes, one of the nation,s most pervasive and costly ... , In an open letter to the President and ...
... , , SAN DIEGO, ... ) today announced that it has priced an underwritten public ... price of $7.50 per share. Net proceeds, after estimated underwriting ... million. Orexigen has granted the underwriter a 30-day option to ...
... 23 At the 2009 American Association of Physicists ... California, Elekta will demonstrate how the company,s comprehensive VMAT ... care with precision and ease. , , ... radiation treatments, Elekta booth 423 will highlight treatment planning ...
Cached Medicine News:Health News:More than 1,000 Underinsured and Uninsured Individuals Receive Free Dental Care 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 4Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 5Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 6Health News:Study provides documentation that tumor 'stem-like cells' exist in benign tumors 2Health News:Study provides documentation that tumor 'stem-like cells' exist in benign tumors 3Health News:NCDP Health Care Reform Recommendations Advocate for Diabetes Prevention, Treatment and Care 2Health News:NCDP Health Care Reform Recommendations Advocate for Diabetes Prevention, Treatment and Care 3Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 3
(Date:5/28/2015)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ... buyers to divest in the United States ... Biomet Discovery® Elbow System assets and Cobalt™ bone cement ... pending acquisition of Biomet, Inc. ("Biomet").  , ... with the Bureau of Competition Staff of the U.S. ...
(Date:5/28/2015)... NEW YORK , May 28, 2015 ... billions developing new drugs and tests, and ... for the instruments that can assist them. This ... research publisher. Kalorama Information said instruments such as ... can assist in the identification of drug ...
(Date:5/28/2015)... 28, 2015  Maetrics ( http://maetrics.com ), a leading ... wrapped up a successful conference, "The cost of non-compliance -- ... today in Zurich . ... its Switzerland -based team, experts provided ... Technology field to an exclusive local audience. The event ...
Breaking Medicine Technology:Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2
Reusable shielded cable...
... A OIA MAX test delivers excellent sensitivity ... Strep with a simple, easy-to-use test that ... of performance, speed, and ease-of-use enables you ... overall costs for diagnosing and treating patients ...
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... The FLU OIA test is a ... diagnosis of Influenza A and B with ... answer in just over 15 minutes. Assay ... specimen flexibility, and performance equivalent to 14-day ...
Medicine Products: